Pegylated thrombopoietin mimetic peptide(Pegylated thrombopoietin mimetic peptide) - 药物靶点：TPO receptor_在研适应症：贫血，血小板减少症，急性髓性白血病_专利_临床

概要

基本信息

药物类型

合成多肽

别名

PEG-TPOM

+ [1]

靶点

TPO receptor

作用机制

TPO receptor激动剂(血小板生成素受体激动剂)

治疗领域

血液及淋巴系统疾病肿瘤

在研适应症

贫血血小板减少症急性髓性白血病+ [1]

非在研适应症-

原研机构-

在研机构

Johnson & Johnson

Montefiore Medical Center

Janssen Pharmaceuticals, Inc.

非在研机构

Janssen Research & Development LLC

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 1277664501

来源: *****

关联

2

项与 Pegylated thrombopoietin mimetic peptide 相关的临床试验

NCT03990519 / Completed临床1期

A Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Volunteers

The purpose of this study is to evaluate the safety and tolerability of a single subcutaneous (SC) dose of JNJ-26366821.

开始日期2019-06-24

申办/合作机构

Janssen Research & Development LLC

EUCTR2007-007520-17-BE / Unknown statusN/A

A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of RWJ-800088 on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thrombocytopenia in Subjects with Non-Small Cell Lung Cancer Receiving Gemcitabine and Either Carboplatin or Cisplatin - n/a

开始日期2008-07-25

申办/合作机构-

100 项与 Pegylated thrombopoietin mimetic peptide 相关的临床结果

登录后查看更多信息

100 项与 Pegylated thrombopoietin mimetic peptide 相关的转化医学

登录后查看更多信息

100 项与 Pegylated thrombopoietin mimetic peptide 相关的专利（医药）

登录后查看更多信息

83

项与 Pegylated thrombopoietin mimetic peptide 相关的文献（医药）

2024-12-31·Platelets

Role of platelet count in a murine stasis model of deep vein thrombosis

Article

作者: Nguyen, Khanh P ; Le-Cook, Anh ; Lorentz, Christina U ; Mathews, Rick ; Hinds, Monica T ; Revenko, Alexey ; Setthavongsack, Naly ; Kaempf, Andy ; Woltjer, Randall L ; Loftis, Jennifer M

Platelets are core components of thrombi but their effect on thrombus burden during deep vein thrombosis (DVT) has not been fully characterized. We examined the role of thrombopoietin-altered platelet count on thrombus burden in a murine stasis model of DVT. To modulate platelet count compared to baseline, CD1 mice were pretreated with thrombopoietin antisense oligonucleotide (THPO-ASO, 56% decrease), thrombopoietin mimetic (TPO-mimetic, 36% increase), or saline (within 1%). Thrombi and vein walls were examined on postoperative days (POD) 3 and 7. Thrombus weights on POD 3 were not different between treatment groups (p = .84). The mean thrombus weights on POD 7 were significantly increased in the TPO-mimetic cohort compared to the THPO-ASO (p = .005) and the saline (p = .012) cohorts. Histological grading at POD 3 revealed a significantly increased smooth muscle cell presence in the thrombi and CD31 positive channeling in the vein wall of the TPO-mimetic cohort compared to the saline and THPO-ASO cohorts (p < .05). No differences were observed in histology on POD 7. Thrombopoietin-induced increased platelet count increased thrombus weight on POD 7 indicating platelet count may regulate thrombus burden during early resolution of venous thrombi in this murine stasis model of DVT.

2024-11-08·JCI Insight

Thrombopoietin mimetic reduces mouse lung inflammation and fibrosis after radiation by attenuating activated endothelial phenotypes

Article

作者: Yang, Weng-Lang ; Tanaka, Kathryn E ; Guha, Chandan ; Eichenbaum, Gary ; Tanaka, Kathryn E. ; English, Jeb ; Dhanikonda, Sriya ; Koba, Wade

Radiation-induced lung injury (RILI) initiates radiation pneumonitis and progresses to fibrosis as the main side effect experienced by patients with lung cancer treated with radiotherapy. There is no effective drug for RILI. Sustained vascular activation is a major contributor to the establishment of chronic disease. Here, using a whole thoracic irradiation (WTI) mouse model, we investigated the mechanisms and effectiveness of thrombopoietin mimetic (TPOm) for preventing RILI. We demonstrated that administering TPOm 24 hours before irradiation decreased histologic lung injury score, apoptosis, vascular permeability, expression of proinflammatory cytokines, and neutrophil infiltration in the lungs of mice 2 weeks after WTI. We described the expression of c-MPL, a TPO receptor, in mouse primary pulmonary microvascular endothelial cells, showing that TPOm reduced endothelial cell-neutrophil adhesion by inhibiting ICAM-1 expression. Seven months after WTI, TPOm-treated lung exhibited less collagen deposition and expression of MMP-9, TIMP-1, IL-6, TGF-β, and p21. Moreover, TPOm improved lung vascular structure, lung density, and respiration rate, leading to a prolonged survival time after WTI. Single-cell RNA sequencing analysis of lungs 2 weeks after WTI revealed that TPOm shifted populations of capillary endothelial cells toward a less activated and more homeostatic phenotype. Taken together, TPOm is protective for RILI by inhibiting endothelial cell activation.

2024-11-01·Small

Surface Engineering Enhances Vanadium Carbide MXene‐Based Nanoplatform Triggered by NIR‐II for Cancer Theranostics

Article

作者: He, Lei ; Zhu, Xiaodong ; Zhang, Jing ; Guo, Jiahao ; Li, Ang ; Li, Wei ; Wang, Fuming ; Zhang, Xide ; Gao, Fu ; Qiu, Zhiwen

AbstractDespite the advantages of high tissue penetration depth, selectivity, and non‐invasiveness of photothermal therapy for cancer treatment, developing NIR‐II photothermal agents with desirable photothermal performance and advanced theranostics ability remains a key challenge. Herein, a universal surface modification strategy is proposed to effectively improve the photothermal performance of vanadium carbide MXene nanosheets (L‐V2C) with the removal of surface impurity ions and generation of mesopores. Subsequently, MnOx coating capable of T1‐weighted magnetic resonance imaging can be in situ formed through surface redox reaction on L‐V2C, and then, stable nanoplatforms (LVM‐PEG) under physiological conditions can be obtained after further PEGylation. In the tumor microenvironment irradiated by NIR‐II laser, multivalent Mn ions released from LVM‐PEG, as a reversible electronic station, can consume the overexpression of glutathione and catalyze a Fenton‐like reaction to produce ·OH, resulting in synchronous cellular oxidative damage. Efficient synergistic therapy promotes immunogenic cell death, improving tumor‐related immune microenvironment and immunomodulation, and thus, LVM‐PEG can demonstrate high accuracy and excellent anticancer efficiency guided by multimodal imaging. As a result, this study provides a new approach for the customization of 2D surface strategies and the study of synergistic therapy mechanisms, highlighting the application of MXene‐based materials in the biomedical field.

100 项与 Pegylated thrombopoietin mimetic peptide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
贫血	临床2期	-	Johnson & Johnson	-
血小板减少症	临床2期	-	Johnson & Johnson	-
急性髓性白血病	临床前	美国	Janssen Pharmaceuticals, Inc.	2019-05-26
急性髓性白血病	临床前	美国	Montefiore Medical Center	2019-05-26
骨髓增生异常综合征	临床前	美国	Janssen Pharmaceuticals, Inc.	2019-05-26
骨髓增生异常综合征	临床前	美国	Montefiore Medical Center	2019-05-26